Simuni T, on behalf of the Parkinson Study Group. A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results. AAN 2019.
Veiligheid en effectiviteit van nabiximols voor spasticiteit bij ‘motor-neuron disease’
apr 2019 | Neuro-musculair